Is there a role for LHRH antagonists in prostate cancer?
نویسنده
چکیده
The recent US Food and Drug Administration (FDA) approval of degarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, has renewed interest in this class of drugs as a prostate cancer therapy. Approval was based on a prospective phase III trial of 610 patients randomized to one of two dosing schedules of degarelix, or standard-of-care monthly leuprolide acetate monotherapy, with initial antiandrogen therapy allowed at the treating physician’s discretion for prevention of clinical flare.[1]
منابع مشابه
Traditional androgen ablation approaches to advanced prostate cancer: new insights.
INTRODUCTION Androgen deprivation therapy (ADT) is a mature therapy for the treatment of advanced prostate cancer, and yet despite many years of use, there is still much about its use, side effects, efficacy, and outcomes for which the urology community does not have answers. MATERIALS AND METHODS A literature search was performed to review ADT use in the modern era, specifically examining ad...
متن کاملLHRH antagonists vs LHRH agonists: which is more beneficial in prostate cancer therapy?
Crawford and Hou[1] review the data on luteinizing hormone-releasing hormone (LHRH) antagonists in prostate cancer. They describe the results of a phase III trial comparing monthly degarelix to monthly leuprolide in men with advanced prostate cancer. Degarelix treatment was associated with a more rapid decline of serum testosterone, and was not associated with an initial surge of serum testoste...
متن کاملControversies surrounding androgen deprivation for prostate cancer.
BACKGROUND Management of metastatic prostate cancer continues to evolve. The widespread use of the prostate-specific antigen (PSA) assay has led to earlier diagnosis and earlier detection of recurrent disease. Debates continue regarding the proper use and timing of endocrine therapy with orchiectomy, estrogen agonists, luteinizing hormone-releasing hormone (LHRH) analogs, LHRH antagonists, and ...
متن کاملEffects of LHRH-A2 and chlorpromazine (dopamine antagonists) on inducing spawning in Caspian Kutum, Rutilus frisii kutum, from the southwest of the Caspian Sea
Caspian kutum, Rutilus frisii kutum, is one of the most commercially important fish species in the Caspian Sea, but there are few reports about the endocrinology of induced spawning in this fish. In the present study, 54 individuals of female broodstocks of Kutum were studied for quantity and quality of propagation index, during March and April 2007. Hormone treatments include: LHRH-A2 (1 ?g kg...
متن کاملUtility of LHRH antagonists for advanced prostate cancer.
INTRODUCTION Androgen deprivation therapy (ADT) is the lynchpin of treatment for advanced prostate cancer. Prescribing physicians and patients have a choice between orchiectomy, luteinizing hormone releasing hormone (LHRH) agonists, combined androgen deprivation (CAD) or LHRH antagonists. MATERIALS AND METHODS Literature relating to the use of LHRH antagonists in the management of prostate ca...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Oncology
دوره 23 7 شماره
صفحات -
تاریخ انتشار 2009